REATA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the "Merger Agreement"), by and among Biogen Inc., a Delaware corporation ("Biogen"), River Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Biogen ("Merger Sub"), and Reata Pharmaceuticals, Inc. ("Reata"), pursuant to which Merger Sub will be merged with and into Reata, with Reata surviving as a wholly-owned subsidiary of Biogen (the "Merger").

REATA PHARMACEUTICALS INC.’s own tally for this item (“1. Proposal No. 1 - The Merger Proposal: To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the " Merger Agreement "), by and among Bioge”): 41,461,455 for, 39,094 against — passed, per its Form 8-K filed September 21, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Merger Proposal was approved by the requisite vote as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 74 managers: 7,695,081 for, 32,500 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 2 managers: 274,517 for.

Description as filed by funds: To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.

REATA PHARMACEUTICALS INC.’s own tally for this item (“3. Proposal No. 3 - The Adjournment Proposal: To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agree”): 40,145,724 for, 1,261,433 against — passed, per its Form 8-K filed September 21, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Although the Adjournment Proposal was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Special Meeting to approve the Merger Proposal, it was approved by the requisite vote as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 74 managers: 6,990,032 for, 705,049 against, 32,500 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 274,468 for.

Description as filed by funds: To approve, on an advisory, non- binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger Agreement.

REATA PHARMACEUTICALS INC.’s own tally for this item (“2. Proposal No. 2 - The Advisory Compensation Proposal: To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Me”): 28,023,999 for, 12,977,053 against — passed, per its Form 8-K filed September 21, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Advisory Compensation Proposal was approved by the requisite vote as follows:”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 74 managers: 1,057,363 for, 6,478,674 against, 191,544 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 187 managers: 9,100,712 for, 7,849,698 against, 233,643 abstained, 29,810 not voted, 1,632 unknown, 5 1 year. Showing the 25 largest; see all in the interactive database.

The 7 asset managers below reported 1,142,909 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.